Observational studyIntensive care medicine2014
Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting.
Observational study in Intensive care medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Population Pharmacokinetics of Tigecycline and Implications for Individualized Therapy Optimization: A Systematic Review.Drug design, development and therapy · 2025Pooled it
- The 2018 Lebanese Society of Infectious Diseases and Clinical Microbiology Guidelines for the use of antimicrobial therapy in complicated intra-abdominal infections in the era of antimicrobial resistance.BMC infectious diseases · 2019Guideline
- Risk factors for tigecycline-associated drug-induced liver injury in critically Ill patients: a 2020-2023 retrospective study from a Chinese hospital.BMC infectious diseases · 2026Article
- Do Obesity Classifications Create the Obesity Paradox? A Scoping Review of Obesity Definitions Applied in Sepsis Research.Clinical obesity · 2026Article
- A novel multivariate logistic model for predicting risk factors of failed treatment with carbapenem-resistantFrontiers in public health · 2024Article
- Population pharmacokinetics of tigecycline in critically ill patients.Frontiers in pharmacology · 2023Article
- Evaluation of Tigecycline Utilization and Trends in Antibacterial Resistance from 2018 to 2021 in a Comprehensive Teaching Hospital in China.Infection and drug resistance · 2023Article
- Tigecycline Dosing Strategies in Critically Ill Liver-Impaired Patients.Antibiotics (Basel, Switzerland) · 2022Article
- Mechanism of Abnormal Coagulation Induced by Tigecycline in Cancer Patients.Frontiers in pharmacology · 2022Article
- Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates.Antimicrobial agents and chemotherapy · 2021Article
- The effect of an antibiotic stewardship program on tigecycline use in a Tertiary Care Hospital, an intervention study.Annals of clinical microbiology and antimicrobials · 2020Article
- Tigecycline Therapy for Multi-drug-ResistantSN comprehensive clinical medicine · 2020Article
- Risk factors with the development of infection with tigecycline- and carbapenem-resistantInfection and drug resistance · 2019Article
- Treatment of severe MRSA infections: current practice and further development.Intensive care medicine · 2017Article
- The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections.World journal of emergency surgery : WJES · 2017Review
- Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference.World journal of emergency surgery : WJES · 2017Review
- Prescription Patterns for Tigecycline in Severely Ill Patients for Non-FDA Approved Indications in a Developing Country: A Compromised Outcome.Frontiers in microbiology · 2017Article
- What's new in multidrug-resistant pathogens in the ICU?Annals of intensive care · 2016Review
- Focus on antimicrobial use in the era of increasing antimicrobial resistance in ICU.Intensive care medicine · 2016Article
- Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.BioMed research international · 2016Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis prospective observational study aimed at describing prescription patterns of tigecycline and patient outcomes in 26 French intensive care units (ICU).
methodsData of consecutive cases of adult patients treated with tigecycline were collected from the initiation until 7 days after the end of treatment. Response to treatment was classified as success, failure or undetermined and analyses were presented according to severity (SOFA score <7 or ≥7). Survival was recorded at 28 days.
resultsA total of 156 patients were included (64% male, age 60 ± 15 years). At inclusion, 53% had a SOFA score ≥7; 93% had received prior anti-infective agents. Tigecycline was given as first-line treatment in 47% of patients, mostly in combination (67%), for intra-abdominal (IAI 56%), skin and soft tissue (SSTI 19%) or other infections. A total of 76% of the treated infections were hospital-acquired. Bacteraemia was reported in 12% of patients. Median treatment duration was 9 days. Tigecycline was prematurely stopped in 42% patients. The global success rate was 60% at the end of treatment, and significantly higher with treatment duration more than 9 days (76 vs. 47%, P < 0.001). Success rate was 65% for patients alive at the end of treatment. Success rates tended to decrease with illness severity, immunosuppression, bacteraemia and obesity. Survival rate at day 28 was 85% in the whole cohort and significantly higher in the less severely ill patients (P < 0.001).
conclusionsTigecycline success rates appear comparable to those reported in clinical studies in ICU with severe infections. Tigecycline could be an alternative in ICU patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.